Flu is the common term for influenza, a contagious viral respiratory illness affecting the nose, throat, and sometimes lungs. Illness severity ranges from mild to severe and can lead to hospitalization or death, especially in high-risk groups. Annual vaccination is a key preventive strategy.
Measles cases in the U.S. reached 2,288 in 2025, the highest since 1992, with 2,104 cases reported in the first half of 2026. Utah has seen 499 cases this year, more than 20% of the national total, driven by pockets of low vaccination. Health officials emphasize vaccination and early symptom recognition to prevent spread.
The FDA reversed its initial rejection of Moderna's mRNA flu vaccine, agreeing to a normal review after public backlash, while a federal judge invalidated the ACIP advisory committee, leaving the US without functioning vaccine oversight. Moderna's vaccine showed 26.6% greater efficacy than standard flu shots in clinical trials.
Ebola Virus Disease remains a public health concern due to its high fatality rate. A new outbreak has been confirmed in Congo’s Ituri province, while early treatment and approved monoclonal antibodies can enhance survival.
The FDA reversed its refusal to review Moderna’s mRNA flu vaccine application and accepted a revised filing with split age cohorts and a post-market study for adults over 65. The reversal came amid broader vaccine regulatory uncertainty and industry concern about unpredictable review timelines.
Calls are growing to bring CAR-T cell therapy to New Zealand as the current trial is set to end later this year. There is no clear path to public availability.
Moderna shares rose after the company reported quarterly results that beat earnings and revenue estimates. The stock move came as investors also weighed an FDA refusal-to-file for its mRNA flu vaccine and ongoing funding concerns.
The FDA plans to make one study the default for some new drug approvals instead of two robust clinical trials. The shift could have its biggest effect on drugs for common ailments.
Moderna will pay $2.25 billion to settle patent disputes with Arbutus Biopharma and Genevant Sciences over lipid nanoparticle technology used in its COVID-19 vaccine. The settlement removes uncertainty for Moderna's vaccine pipeline and sent the stock surging over 11%. The company expects to end 2026 with $4.5-$5 billion in cash and return to revenue growth by year-end.
Researchers have created a nasal vaccine platform that protects mice against flu, COVID-19, SARS, and bacterial infections by activating both innate and adaptive immune systems, offering a fundamentally different approach to disease prevention.
Children with obstructive sleep apnea face nearly twice the risk of contracting influenza or COVID-19 compared to controls, with increased vulnerability persisting even after adenotonsillectomy, according to a five-year study of over 1 million children.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07147517 |
Preparedness Through Respiratory Virus Epidemiology and Community Engagement |
RECRUITING | |
| NCT07007377 |
Can the Ergometric Test in Flu-like Syndrome Help in the Outcome Analysis of Unvaccinated Patients |
COMPLETED | |
| NCT06626321 |
Behavioral Economics to Improve Flu Vaccination Using EHR Nudges Replication |
COMPLETED | NA |
| NCT06385821 |
A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus |
COMPLETED | PHASE3 |
| NCT06158659 |
Improved Immunology Outcomes Associated With Lactoferrin Fortified With HMO in Infant Formula |
COMPLETED | NA |
| NCT06057727 |
Behavioral Economics to Improve Flu Vaccination Using EHR Nudges |
COMPLETED | NA |
| NCT05473325 |
Benchtop NMR Spectroscopy for Assessment of Clinical Human Pathologies (BRANCH-P STUDY) |
UNKNOWN | |
| NCT05435144 |
Elderberry for Immune Support |
UNKNOWN | NA |
| NCT05417997 |
Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients |
COMPLETED | PHASE3 |
| NCT04515446 |
Quantification of Viral Load in the Upper Respiratory Tract in Patients Treated With Olsetamivir for Influenza |
ACTIVE_NOT_RECRUITING | NA |
